PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34275396-11	2021	Early phase studies suggested the combinations of acalabrutinib with a CD20 antibody and venetoclax led to high rates of undetectable minimal residual disease in the bone marrow in CLL patients and might provide a fixed-duration therapeutic option for patients with CLL.	acalabrutinib	50-63	keratin 20	Homo sapiens	71-75	
30089638-11	2018	CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib.	acalabrutinib	80-93	keratin 20	Homo sapiens	0-4	
34268530-6	2021	Acalabrutinib is approved as monotherapy in the R/R or TN setting, and in the TN setting can be combined with the anti-CD20 monoclonal antibody obinutuzumab.	acalabrutinib	0-13	keratin 20	Homo sapiens	119-123	
33093947-15	2020	Discussion: ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL.	acalabrutinib	53-66	keratin 20	Homo sapiens	203-207	
31915195-1	2020	Acalabrutinib is a selective irreversible Bruton tyrosine kinase inhibitor that does not affect interleukin-2 associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies.	acalabrutinib	0-13	keratin 20	Homo sapiens	250-254	
28642301-0	2017	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.	acalabrutinib	46-59	keratin 20	Homo sapiens	154-158